Why it Matters
Swiss pharmaceutical giant Lonza Group is expanding its lobbying presence by hiring top-tier firm Brownstein Hyatt Farber Schreck LLP while maintaining existing relationships. This signals heightened concern about supply chain vulnerabilities and trade policies affecting global healthcare manufacturing.
By the Numbers
Lonza has spent $160,000 on federal lobbying since July 2024. The company now works with two firms:
- Crowell & Moring LLP: Primary firm (July 2024-July 2025), $160,000 spent
- Brownstein Hyatt Farber Schreck LLP: New addition (October 2025-present)
The new lobbying team includes three experienced professionals:
- Stephen M. Holland: Former House Energy and Commerce Committee senior health counsel
- W. Scott Douglas: Healthcare supply chain specialist
- Aaron Clifford Cummings: Former Senate Judiciary Committee counsel
Broader Context
Congress is laser-focused on pharmaceutical supply chain vulnerabilities. Recent hearings revealed 83% of top generic drugs have no domestic active ingredient source. Lawmakers from both parties are pushing legislation to reduce China dependence and strengthen domestic manufacturing capabilities after COVID-19 exposed critical weaknesses.
The Agenda
Lonza is lobbying on manufacturing and trade issues, specifically supply chain management and intellectual property protection. The company previously focused heavily on the BIOSECURE Act through Crowell & Moring LLP. No specific legislation is currently listed in the new registration filing.
Competitive Landscape
Lonza joins a crowded field of pharmaceutical companies lobbying on similar issues. Eli Lilly & Co. targets “multi-lateral threats to IP.” Biogen Inc. focuses on stronger IP protections. The Pharma and Biopharma Outsourcing Association discusses onshoring initiatives and tariff impacts.
Between The Lines
Congress is advancing multiple bills affecting Lonza’s interests. The China Technology Transfer Control Act would restrict biotech exports to China. The Medical Supply Chain Resiliency Act aims to eliminate duties on medical goods from trusted partners. Sen. John Cornyn celebrated Eli Lilly’s $6.5 billion Texas investment as supply chain strengthening. Sen. Thom Tillis returned as Chairman of the Senate Judiciary Subcommittee on Intellectual Property.
The Bottom Line
Lonza’s lobbying expansion reflects the high stakes around pharmaceutical policy. With bipartisan momentum building for supply chain reforms and IP protection, the Swiss manufacturer is positioning itself for potentially disruptive legislative changes.
All data used in this article came from Legis1. Request a demo to learn more!
Spot something wrong? Report an issue with this article